Core D provides the platform and infrastructure in which CRC investigators at multiple institutions develop, implement, execute, monitor, and analyze CRC clinical and laboratory data from subjects treated on clinical trials and enrolled in the CRC Tissue Bank. Furthermore, the investigators of Core D will identify and develop clinical research strategies utilizing new agents and combinations, with the ultimate goal of curing CLL. A primary objective of Core D is to provide indispensable clinical input and focus for collection and management of clinical data for CRC Projects and Tissue Bank. A web-based CRC Integrated Information Management System(CIMS) was developed in collaboration with the CRC Biomedical Informatics (CBMI) Workgroup. This system was designed to collect and manage clinical and laboratory information for patients samples stored in the CRC Tissue Bank and for patients treated on CRC clinical trials. This system enables collection of clinical and laboratory information from each CRC site via the Internet in real-time. Current and proposed efforts will be to transition to automated methods of data collection. Clinical research-based objectives will utilize clinical and laboratory information to develop new prognostic models, treatments and treatment objectives for patients with CLL. Core D will assure accurate and complete data collection for the following purposes: reports;patient scheduling/calendaring;data exports that facilitate analyses and reporting;and patient data monitoring and auditing and assuring regulatory and sponsor compliance required by each CRC clinical trial. Since last funding, the CRC has complete 5 clinical studies which are published, in follow-up, or in manuscript preparation. The CRC currently has 4 active clinical trials as detailed in this Core D write-up. Finally, there are 14 clinical trials in development as described in this Core D write-up and in each Project description throughout the grant application. Because there are circulating tumor cells that can be easily and readily accessed and given the scientific quality of CRC Project investigators, the CRC is uniquely positioned to do detailed correlative studies for patients treated on clinical trial in order to address mechanism of action questions and hypotheses testing and confirmation.

Public Health Relevance

The Clinical Core D is fundamental and essential to the translational research proposed in this Program Project. Clinical data associated with Tissue Bank samples and clinical-translational data from patients treated on clinical trials are fundamental and essential to conduct of this CRC Program Project. All Projects utilize patient samples from the Tissue Bank and all Projects propose translational studies related to ongoing or planning clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510
Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970
Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39
Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736

Showing the most recent 10 out of 562 publications